• OptimumBank has delivered record earnings and profitability, with 2024 net income of $13.1 million and Core ROAE above 23 percent, all achieved without credit losses for the past seven years.
• The company expects to surpass $1.2 billion in assets by the end of 2025 and projects continued growth to $1.5 to $1.6 billion by year-end 2026, supported by a clean balance sheet and no exposure to long-dated, low-yield bonds.
• OptimumBank achieved SBA Preferred Lender status in just over two years and grew its SBA lending program from zero, demonstrating rapid execution and small business demand.
• Strategic investments in a new digital core platform are expected to enhance scalability and user experience.
• OptimumBank maintains a strong capital position and disciplined underwriting, with Tier 1 capital well above regulatory minimums and significant institutional ownership, including a notable position held by Alliance Bernstein.
• OPHC trades at a significant discount relative to peers, despite stronger growth, credit quality, and returns, creating an attractive entry point for investors.

OptimumBank Holdings (NYSE American: OPHC) is a single bank holding company that owns 100% of OptimumBank, a community bank headquartered in Fort Lauderdale, Florida. OptimumBank offers relationship-driven banking available in person, by phone, and online, serving both local and international clients by offering an alternative to the high fees and impersonal service of larger institutions. Its expertise in real estate and commercial lending has made it a preferred partner for borrowers seeking knowledgeable, accessible financial support.

Driven by disciplined execution and a commitment to local relationships, OptimumBank has experienced substantial organic growth, positioning itself as one of the fastest-growing community banks in the region. The company has surpassed $1 billion in total assets and remains focused on scaling efficiently, maintaining sound credit quality, and delivering strong returns for shareholders.

Looking ahead, the bank is embracing technology modernization while remaining grounded in the principles of relationship-based banking. A new open-architecture core platform, targeted loan expansion, and sustained deposit growth are key pillars of its forward strategy.

Products

OptimumBank offers a full suite of business and personal banking solutions, including Business Banking, Business Lending, SBA Lending Solutions, Treasury Management, and Personal Banking. Its lending focus includes commercial real estate, multifamily, construction, residential, and consumer loans.

The bank achieved Preferred Lender status with the Small Business Administration in just over two years—an uncommon accomplishment—and rapidly scaled its SBA lending operations from zero in record time. Its treasury services and deposit products are supported by a stable core funding base, with a growing percentage of noninterest-bearing demand deposits.

In late 2025, OptimumBank is rolling out a next-generation core banking platform with API-based architecture, enabling paperless processing, streamlined onboarding, and enhanced treasury management tools.

OptimumBank is deeply engaged in the community, providing support to organizations such as Habitat for Humanity of Broward, along with schools, synagogues, and many other nonprofits that are important to its customers and neighbors.

Market Opportunity

The U.S. community banking sector represents a multi-trillion-dollar opportunity, especially in underserved regions where local institutions continue to consolidate. South Florida’s real estate market and growing population create robust demand for personalized commercial lending, construction loans, and deposit services.

According to Mordor Intelligence, the U.S. commercial banking market is expected to grow from $732.5 billion in 2025 to $915.45 billion by 2030, reflecting a compound annual growth rate (“CAGR”) of 4.56%. Within this landscape, OptimumBank is well-positioned to benefit from regional consolidation and rising customer dissatisfaction with national banks.

OptimumBank’s continued investments in talent, technology, and compliance infrastructure ensure scalability as it targets its next major milestone: becoming a top 200 publicly traded bank in the United States. The bank has maintained a track record of net recoveries in recent years, with no loan losses in over seven years and no defaults in its current loan portfolio. In addition, OptimumBank has near-zero exposure to long-dated, low-yield bonds, avoiding the balance sheet drag that has pressured many regional peers.

Leadership Team

Moishe Gubin, Chairman of OptimumBank Holdings, has been a director since 2010. He is also the CEO of Strawberry Fields REIT and previously served as CFO of Infinity Healthcare Management. Gubin is a licensed CPA in New York and the founder of the Midwest Torah Center.

Timothy Terry, President and CEO, has led OptimumBank since 2013 and has over 35 years of banking experience. He previously held senior roles at Enterprise Bank of Florida and other financial institutions, with a background in lending, branch administration, and sales.

Elliot Nunez, EVP and CFO, joined the bank in 2020. He previously served as CFO for Brickell Bank and Mellon United National Bank and worked at KPMG. Nunez is a licensed CPA and Chartered Global Management Accountant.

For more information, visit the company’s website at OptimumBankInvestors.com.

NOTE TO INVESTORS: The latest news and updates relating to OPHC are available in the company’s newsroom at https://ibn.fm/OPHC

• Recent warrant exercises at $6.43 generated $5.3 million, signaling investor conviction in AVERSA(TM) Fentanyl ahead of NDA filing
• AVERSA(TM) is a abuse-deterrent solution for transdermal patches, addressing a longstanding gap in pain management safety
• Strategic funding positions Nutriband to complete development and FDA submission, targeting $80–200 million in peak U.S. annual sales

The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially important.

Market Confidence Meets Innovation

Nutriband (NASDAQ: NTRB) recently secured $5.3 million through warrant exercises at $6.43 per share, a voluntary move by investors that underscores faith in the company’s trajectory. Unlike forced dilutive financings common in biotech, warrant exercises represent active investor choice, signaling conviction in Nutriband’s ability to deliver value.

The funding comes at a pivotal moment, providing resources to finish clinical development and support a New Drug Application (“NDA”) for AVERSA(TM) Fentanyl, Nutriband’s flagship product. This alignment of financing with regulatory milestones strengthens the company’s ability to advance without compromising shareholder value.

First-of-Its-Kind Abuse-Deterrent Patch

Opioid abuse remains a public health crisis, and while oral medications have incorporated deterrent features, transdermal patches have remained vulnerable since their debut in the 1990s. Conventional fentanyl patches can be manipulated (e.g., cut, heated, or chemically altered) creating significant risks of misuse and diversion.

Nutriband’s AVERSA(TM) technology directly addresses this gap. The system integrates aversive agents into the patch, triggering deterrent effects if tampered with. Unlike single-mechanism solutions, AVERSA(TM) employs multiple barriers, making circumvention significantly more difficult. This multi-layered design positions it as the first comprehensive abuse-deterrent patch on the market.

As a platform technology, AVERSA(TM) can be adapted across other transdermal products, offering commercial potential beyond fentanyl while addressing a broader pharmaceutical safety need.

Regulatory Pathway and Market Potential

Analysts project AVERSA(TM) Fentanyl could achieve $80–200 million in peak annual U.S. sales. That opportunity stems from the existing fentanyl patch market combined with payer and provider demand for safer alternatives.

The company is pursuing approval via the FDA’s 505(b)(2) pathway, which leverages existing fentanyl safety data while requiring demonstration of abuse-deterrent efficacy. Recent FDA guidance on abuse-deterrent formulations provides clearer parameters, reducing uncertainty for developers with sound scientific strategies.

Healthcare trends also favor Nutriband’s positioning. Hospitals, insurers, and policymakers increasingly prioritize abuse-deterrent products, creating pathways for premium pricing and preferential formulary inclusion.

Manufacturing Scale Through Partnership

Nutriband’s collaboration with Kindeva Drug Delivery adds critical execution strength. Kindeva specializes in complex transdermal manufacturing, including advanced abuse-deterrent systems. This partnership reduces operational risk, accelerates readiness for commercialization, and allows Nutriband to focus on clinical and regulatory execution.

For a product requiring precise integration of deterrent mechanisms, working with an experienced manufacturing partner enhances credibility with regulators and payers while ensuring scalability.

Platform Expansion Opportunities

While AVERSA(TM) Fentanyl is the immediate focus, the broader opportunity lies in applying AVERSA(TM) across other controlled substances delivered via patches. This could create licensing opportunities with larger pharmaceutical partners, diversifying revenue beyond direct product sales.

As the industry shifts toward heightened safety requirements, Nutriband’s first-mover advantage in transdermal abuse deterrence offers sustainable competitive positioning. The platform approach ensures long-term optionality across multiple indications.

Investment View: Inflection Point Ahead

Nutriband is approaching a key convergence of factors: validated innovation, strong investor support, a defined regulatory pathway, and commercial scalability through partnership. The recent $5.3 million in warrant proceeds reflects external confidence that the company is positioned to cross its most critical milestones.

With AVERSA(TM) Fentanyl potentially becoming the world’s first abuse-deterrent fentanyl patch, Nutriband targets a meaningful commercial opportunity while addressing urgent public health needs. The platform’s expansion potential further strengthens the long-term investment case.

In short, Nutriband is no longer just a development-stage story; it’s a company moving into the decisive phase where innovation meets real-world validation.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

• Modern golfers rely on a range of innovations to enhance every aspect of their performance.
• Newton Golf Company has embraced the ideals of innovation and high tech, applying them directly to the design and production of its golf equipment.
• In addition to equipment, Newton Golf integrates technology into its customer experience, training and education services.

Golf is evolving faster than ever, thanks to advancements in technology that are reshaping how players train, compete and enjoy the sport. Newton Golf Company (NASDAQ: NWTG) is at the forefront of this transformation, blending innovative technology with traditional craftsmanship to produce high-performance golf equipment. The company’s focus on incorporating precision engineering, data-driven design and advanced materials into its clubs and accessories is helping golfers of all skill levels improve their game and experience the sport in new ways.

The importance of technology in golf cannot be overstated. Modern players rely on a range of innovations, from smart sensors and launch monitors to advanced club materials and course management tools, to enhance every aspect of their performance (https://ibn.fm/BeQJ8). Launch monitors, for example, provide real-time data on ball speed, launch angle, spin rate and shot trajectory, allowing golfers to make precise adjustments that can lower their scores significantly. Some studies suggest that golfers who use technology-driven practice tools can improve their accuracy and distance control by up to 15% over a season. Additionally, virtual simulators and swing analysis software allow players to practice in controlled environments, offering detailed feedback on swing mechanics without the need for constant on-course play.

Golf technology is also transforming the way courses are designed, maintained and experienced. Smart irrigation systems, automated mowing equipment and environmental sensors ensure optimal water usage, reduce maintenance costs and create more consistent playing surfaces.

GPS-enabled course mapping and digital scorecards provide players with precise distances to hazards and greens, helping them make more strategic decisions during rounds. Even wearable technology, such as smart watches and sensors embedded in gloves or shoes, offers insights into posture, tempo, and swing consistency, enabling golfers to develop a more efficient and repeatable stroke.

Newton Golf Company has embraced the ideals of innovation and high tech, applying them directly to the design and production of its golf equipment (https://ibn.fm/PGmFy). The company’s clubs feature high-tech materials engineered to maximize energy transfer, increase ball speed and optimize launch conditions. By leveraging computer-aided design and rigorous biomechanical testing, Newton Golf ensures that each club provides the perfect balance of power, control and feel. For example, their motion driver shafts feature Newton’s proprietary Symmetry 360 design, virtually eliminating any spine and ensuring consistency from shot to shot, while the company’s unique Dot System enables users to select the shaft flex that was specifically designed for their game. Such precision engineering translates into longer drives, improved accuracy and more confidence on the course.

In addition to equipment, Newton Golf integrates technology into its customer experience. The company offers swing analysis tools and fitting systems that help golfers select the ideal clubs based on their individual swing profile. These solutions combine motion capture, sensor data and proprietary algorithms to provide actionable recommendations, ensuring that every golfer can perform at their best. By merging traditional craftsmanship with state-of-the-art technology, Newton Golf distinguishes itself as a company committed to innovation while maintaining the tactile feel and aesthetics that golfers value.

The company’s commitment to technology also extends to training and education. Newton Golf provides resources that teach players how to interpret data, make adjustments and leverage technology to strategically improve their game. Whether it’s through online tutorials, on-site fitting sessions or interactive club testing experiences, Newton Golf empowers golfers to understand and utilize the science behind their equipment. This holistic approach to performance improvement helps players of all skill levels unlock their potential, making golf more accessible, engaging, and rewarding.

As the sport continues to evolve, companies such as Newton Golf demonstrate the transformative power of technology. From high-performance clubs designed with precision engineering to advanced swing analysis and fitting tools, Newton Golf’s innovations are helping players improve accuracy, distance, and consistency. By embracing technological advancements while honoring the traditions of the game, Newton Golf is shaping the future of golf, offering equipment and solutions that enhance performance, enjoyment and engagement for golfers around the world.

For more information, visit www.NewtonGolfCo.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

• OptimumBank Holdings, Inc. posted Q2 2025 net earnings of $3.6 million, or $0.31 per basic share.
• Net interest margin rose to 4.32%, reflecting improved deposit pricing and asset yields.
• Total deposits increased by $25.93 million in the quarter, reaching $878.87 million.
• Noninterest income rose to $1.83 million, supported by loan sales and prepayment fees.
• Capital levels remain strong, with Tier 1 Capital to Total Assets at 11.89%.

OptimumBank Holdings (NYSE American: OPHC), a single bank holding company that owns 100% of community bank OptimumBank, headquartered in Fort Lauderdale, Florida, reported higher earnings and positive financial results for the second quarter of 2025, highlighting steady growth in deposits and improved margins.

According to the company’s latest financial update, net earnings for the quarter totaled $3.6 million, or $0.31 per basic share and $0.29 per diluted share. While this was slightly below the $3.87 million posted in the first quarter, it exceeded the $3.5 million recorded in the same period last year (https://ibn.fm/cyTyR).

For the first half of 2025, OptimumBank generated $7.47 million in earnings, an increase of $1.6 million compared with the same period in 2024. The improvement was largely driven by $3.18 million in higher net interest income and a $0.63 million boost in noninterest income.

Net interest income rose to $10.24 million in Q2, supported by stronger yields on loans and lower costs on interest-bearing liabilities. The bank’s net interest margin expanded to 4.32%, up from 4.06% in Q1. Yields on interest-earning assets increased to 6.57%, while the cost of interest-bearing liabilities declined to 3.49%.

This combination reflects management’s focus on disciplined deposit pricing and balance sheet optimization. Return on average assets came in at 1.48% for the quarter, slightly below 1.62% in the previous quarter but still consistent with strong profitability metrics for a community bank.

Deposits grew by $25.93 million in the quarter, reaching $878.87 million by June 30, 2025. Compared with the same quarter in 2024, deposits are up $116.22 million. Noninterest-bearing demand deposits also grew, reaching $259.82 million.

At the same time, the company reduced reliance on borrowings, cutting average borrowings from $32.22 million in Q1 to $2.22 million in Q2. This shift underscores the bank’s emphasis on core funding and balance sheet strength.

While overall gross loans declined by $15.68 million in the quarter, portfolio composition is shifting. Consumer and multifamily lending segments expanded, with balances growing by $7.99 million and $4.71 million respectively. These gains were offset by declines of $19.21 million in land and construction loans and $5.04 million in residential real estate lending.

The reduction was tied to loan payoffs and the resolution of a $5.6 million nonperforming loan. Management indicated that the changes create opportunities to redeploy capital into higher-yielding segments of the portfolio.

Noninterest income reached $1.83 million, a quarterly increase of $0.6 million, primarily driven by gains on sales of government-guaranteed loans and loan prepayment fees. Noninterest expenses also rose, totaling $6.18 million, reflecting higher staffing and infrastructure investments aimed at long-term scalability.

The bank’s efficiency ratio stood at 51.18%, showing continued cost discipline even as operating expenses increased. Credit quality remained solid in Q2. Credit loss expense increased to $1.04 million due to a reserve on a specific commercial loan, but net recoveries of $25,000 were recorded as charge-offs remained modest. The allowance for credit losses totaled $9.34 million, or 1.19% of total loans.

Capital levels were strong, with stockholders’ equity rising to $111.35 million and Tier 1 Capital to Total Assets at 11.89%, well above regulatory requirements.

OptimumBank reported total assets of $999 million at the end of the second quarter, just shy of the $1 billion milestone. Since quarter-end, the Bank has surpassed that threshold, underscoring its position as one of the fastest-growing community banks in South Florida. Its relationship-based business model, complemented by ongoing technology investments, continues to drive growth. Later this year, the Bank plans to launch a new open-architecture core banking platform, with API-driven features designed to streamline paperless processes, enhance onboarding, and strengthen treasury management capabilities.

Chairman Moishe Gubin emphasized the bank’s resilience despite industry headwinds. “Although overall loan balances declined this quarter due to the payoff of older, lower-yielding loans, we remain well positioned to redeploy capital into higher-return opportunities,” he said in the earnings release. “Our results demonstrate our ability to manage a growing asset base while maintaining solid credit quality and capital strength.”

For more information, visit the company’s website at OptimumBankInvestors.com.

NOTE TO INVESTORS: The latest news and updates relating to OPHC are available in the company’s newsroom at https://ibn.fm/OPHC

• New partnership allows VMAR to “unite electric boats, toys and watersports equipment under one roof.”
• The new EV division at Nautical Ventures focuses on offering high-performance electric water toys, with the Seabob serving as its centerpiece.
• VMAR’s EV division’s collaboration with Nautical Ventures ensures that customers receive proper support, training and maintenance for their electric watercraft.

The electric revolution is no longer confined to cars and trucks — it’s making waves in the boating world. As demand grows for sustainable, high-performance alternatives to gas-powered watercraft, Vision Marine Technologies (NASDAQ: VMAR) is stepping forward with a bold move. The company has launched a dedicated electric vehicle (“EV”) division at Nautical Ventures, introducing the Seabob as its flagship electric water toy (https://ibn.fm/n399w). With this initiative, Vision Marine is reinforcing its leadership in the rapidly expanding electric marine market, where innovation and sustainability are becoming the new standard.

“Our vision goes far beyond propulsion,” said Vision Marine CEO and cofounder Alexandre Mongeon. “We are building a complete electric ecosystem for boaters, covering sales, service, aftersales care and on-water experiences. Through Nautical Ventures, we can unite electric boats, toys and watersports equipment under one roof. The renewed Seabob dealer agreement demonstrates the type of premium, innovative products we are bringing into this division to complement our boat offerings and deliver unmatched value to consumers and partners.”

The new EV division at Nautical Ventures focuses on offering high-performance electric water toys, with the Seabob serving as its centerpiece. Known for its speed, maneuverability and eco-friendly operation, the Seabob is a submersible watercraft that propels users through the water using an electric motor, producing no direct emissions and generating minimal noise. By partnering with Nautical Ventures, Vision Marine gains access to a wide consumer base of boating enthusiasts, enabling them to showcase the benefits of electric watercraft in real-world recreational settings. This launch represents a strategic step toward normalizing electric propulsion in recreational boating and highlights the company’s commitment to environmentally sustainable leisure products.

The broader electric marine market is experiencing significant growth. Analysts project that the global electric boat market could exceed $14 billion by 2030, driven by rising environmental awareness, regulatory incentives and consumer demand for quieter, more efficient boating options (https://ibn.fm/DiDef). Electric outboards, such as those offered by Vision Marine, provide a compelling value proposition, including lower maintenance costs due to fewer moving parts, reduced fuel expenses and the elimination of oil changes and gasoline handling. The quiet operation of electric motors also enhances the recreational experience by reducing underwater noise pollution, which benefits both marine life and passengers.

Vision Marine Technologies is taking a multipronged approach to capture this growing market. Beyond hardware innovation, the company is investing in user experience, service infrastructure and partnerships. VMAR’s EV division’s collaboration with Nautical Ventures ensures that customers receive proper support, training and maintenance for their electric watercraft. Vision Marine is also exploring additional partnerships with boat manufacturers, marinas and distributors to expand the adoption of its motors and boats across North America and eventually globally.

Founded in 2018, Vision Marine Technologies has emerged as a leading innovator in the electric marine propulsion sector. The company designs and manufactures electric outboard motors and electric boats aimed at reducing environmental impacts while delivering high-performance experiences (https://ibn.fm/vtvq8). VMAR’s flagship E-Motion 180E motor provides a fully electric alternative to traditional outboard engines, capable of delivering instantaneous torque and smooth acceleration for a variety of recreational watercraft. 

Vision Marine also produces the E-Motion 180E+ and E-Motion 300E motors, which cater to different power requirements and boat sizes. Beyond propulsion systems, Vision Marine has collaborated with Massimo Marine to introduce the first commercial electric pontoon platform, further cementing its presence in the electric boating sector. 

Sustainability is central to Vision Marine’s mission. By replacing gas-powered engines with clean electric propulsion, the company directly reduces greenhouse gas emissions and local air pollution. Its products also contribute to protecting aquatic environments by minimizing the release of oil, gasoline and other contaminants commonly associated with traditional engines. The company’s vision aligns with broader global trends toward electrification of transportation, where electrification of marine vessels is increasingly recognized as a critical step in reducing overall carbon footprints.

Looking forward, Vision Marine Technologies plans to continue expanding its product lineup and market reach. The company is focused on refining motor technology, increasing battery efficiency and exploring new electric watercraft models that can serve both recreational and commercial sectors. With the launch of its dedicated EV division and the addition of the Seabob, Vision Marine is proving that electric propulsion can offer the excitement and performance of traditional boating while aligning with modern sustainability goals. As electric marine technology continues to advance, Vision Marine Technologies is well-positioned to be a leading force in reshaping the future of recreational and professional boating.

For more information, visit www.VisionMarineTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR

• At its core, Soligenix is a late-stage biopharmaceutical company that thrives at the intersection of urgent medical need and scientific innovation.
• SNGX’s Specialized BioTherapeutics division is anchored by its proprietary HyBryte(TM) (“SGX301”), a novel photodynamic therapy for CTCL.
• Soligenix’s Public Health Solutions division positions the company as an important contributor to biodefense and emerging infectious disease.

Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline (https://ibn.fm/YGu4N). The presentation underscores Soligenix’s dual focus: pioneering therapies for rare diseases that lack adequate treatment options while simultaneously developing critical vaccines and countermeasures for emerging infectious threats and bioterrorism risks. This combination sets the company apart as both a champion for underserved patient populations and a strategic partner in global public health preparedness.

At its core, Soligenix is a late-stage biopharmaceutical company that thrives at the intersection of urgent medical need and scientific innovation. The latest presentation highlights the company’s progress across two key business segments: Specialized BioTherapeutics, which is focused on orphan diseases and dermatological conditions, and Public Health Solutions, which develops heat-stable vaccines for high-consequence pathogens. This dual-track approach is more than just diversification—it represents a deliberate strategy to address areas where human and societal stakes are high.

The Specialized BioTherapeutics division is anchored by the company’s proprietary HyBryte(TM) (“SGX301”), a novel photodynamic therapy for cutaneous T-cell lymphoma (“CTCL”). In its first phase 3 clinical trial, HyBryte produced statistically significant results, marking the first therapy of its kind to reach this stage. A second confirmatory phase 3 trial is actively enrolling to support potential worldwide marketing approvals, reinforcing the company’s commitment to bringing HyBryte to market with robust data. With the European Medicines Agency (“EMA”) already agreeing to Soligenix’s proposed regulatory package and U.S. Food and Drug Admission (“FDA”) discussions ongoing, HyBryte is positioned to potentially become the first approved therapy in its class (https://ibn.fm/gIaZ3). Its commercial potential is substantial, given that CTCL patients face limited options and a high unmet need. 

Building on this, Soligenix is also advancing SGX302 for psoriasis, a therapy that leverages the same innovative mechanism but applies it to a vastly larger market estimated at more than $27 billion globally (https://ibn.fm/EXkZF). Early clinical data have been encouraging, and the company is advancing a phase 2a study to further validate the therapy’s promise. In addition, the company is making headway with SGX945 (dusquetide), a novel innate defense regulator targeting oral ulcers in Behçet’s disease, a rare but debilitating autoimmune condition. The FDA recently granted orphan drug designation for SGX945 following positive phase 2a results, further solidifying the drug’s potential as a first-in-class treatment option for patients who currently have limited alternatives (https://ibn.fm/AgdPg).

While these rare disease programs could drive near-term commercial success, Soligenix’s Public Health Solutions division positions the company as an important contributor to public health. Here, the company is advancing RiVax(R), a ricin toxin vaccine candidate that has received both FDA orphan drug and fast track designations. Ricin remains one of the most lethal bioterror threats, and RiVax’s development to date has been heavily supported by U.S. government contracts, reflecting both its scientific merit and strategic necessity. 

Complementing RiVax are vaccine programs targeting filoviruses such as Ebola, Marburg and  COVID-19. All of these utilize Soligenix’s proprietary ThermoVax(R) technology, which enables heat-stable vaccines, an innovation that could dramatically reduce cold-chain distribution challenges in both emergency and routine immunization campaigns.

The Soligenix presentation doesn’t shy away from the broader industry context. Between 2018 and 2024, the global digital and biotech markets surged, with funding for innovative therapies and health security reaching new heights. For Soligenix, this environment provides both opportunities and challenges: Competition in the biotech space is intense, but its niche focus on rare diseases and public health solutions gives it a defensible position that few peers can claim. In fact, the company estimates the combined annual market potential for its current pipeline to be around $2 billion, underscoring the commercial upside if even a fraction of its therapies achieve regulatory approval.

What makes Soligenix particularly compelling is not just the breadth of its science but the consistency of its execution. Orphan and rare disease programs often require navigating complex regulatory frameworks and working closely with patient advocacy groups. Meanwhile, public health initiatives depend on sustained government support, long-term funding and alignment with national security priorities. The presentation makes clear that Soligenix has been able to advance on both fronts, maintaining momentum in its late-stage rare disease trials while having secured nondilutive government funding to advance its vaccine platforms.

In sum, Soligenix’s latest corporate presentation paints a portrait of a company that is steadily building value at the intersection of science, medicine and global health and security. From its innovative dermatology pipeline to its pioneering vaccines, Soligenix is moving closer to the pivotal moment when science translates into real-world solutions. For patients facing rare diseases and for societies confronting public health threats, the company’s progress offers a much-needed source of optimism, and for investors, the presentation presents a clear view of a biotech firm charting a distinct and potentially transformative path.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• The LOI sets the stage for a potential decade of supply from Critical Metals’ Tanbreez project in southern Greenland.
• The Louisiana facility is being designed as a first-of-its-kind rare earth separation plant capable of processing both light and heavy rare earths at commercial scale.
• The timing of this agreement is particularly significant given the surging demand for rare earths globally.

A decade-long supply agreement linking Greenland’s vast rare earth deposits with Louisiana’s growing role as a U.S. processing hub is poised to shift the balance of critical mineral independence in North America. Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) has signed a letter of intent (“LOI”) with Critical Metals Corp. to secure up to 10,000 metric tons of heavy rare earth concentrate annually starting in 2027, anchoring a reliable feedstock for its Department of Defense (“DoD”)–supported Louisiana facility (https://nnw.fm/MfIJW) (https://ibn.fm/Ufn3x). With Greenland’s Tanbreez Project recognized as one of the world’s largest undeveloped rare earth resources and Louisiana strategically positioned as an industrial gateway, this agreement underscores Ucore’s mission to build a fully integrated, North American supply chain for the technologies that will power the clean energy future and strengthen national security.

The newly signed nonbinding LOI sets the stage for a potential decade of supply from Critical Metals’ Tanbreez project in southern Greenland, which hosts a massive deposit of eudialyte rich in heavy rare earth elements. Under the terms of the agreement, shipments of up to 10,000 metric tons per year would begin in 2027 and extend for at least 10 years. This long-term vision is designed not only to provide stability for Ucore’s processing operations but also to offer assurance to end users across defense, clean energy and advanced manufacturing sectors that reliable, non-Chinese sources of rare earths are on the horizon.

Rare earth elements, including dysprosium and terbium contained within heavy rare earth concentrates, are indispensable to technologies such as permanent magnets used in electric vehicles, wind turbines and defense applications. Currently, more than 90% of the world’s heavy rare earth processing occurs in China (https://ibn.fm/wEUsu), leaving Western economies vulnerable to supply disruptions. By securing feedstock from Greenland and advancing its state-of-the-art Strategic Metals Complex in Alexandria, Louisiana, Ucore is taking a critical step toward reshaping the supply-demand balance and reducing dependence on foreign sources.

The Louisiana facility, which has already received significant funding commitments from the U.S. Department of Defense (https://ibn.fm/Copc5), is being designed as a first-of-its-kind rare earth separation plant capable of processing both light and heavy rare earths at commercial scale. According to Ucore, the facility will utilize its proprietary RapidSX(TM) separation technology, which has been developed and tested over the past decade as a cost-efficient and scalable alternative to traditional solvent extraction. By combining this advanced technology with a long-term feedstock arrangement from Critical Metals, Ucore is positioning Louisiana as a cornerstone of the North American rare earth supply chain.

The Tanbreez Project, held by Critical Metals Corp., is widely regarded as one of the largest untapped rare earth deposits in the world, with more than four billion tons of ore containing significant concentrations of heavy rare earths (https://ibn.fm/QOKIr). Its location in Greenland, a territory with close political and trade ties to the West, makes it a strategically attractive partner for Ucore’s mission. A steady stream of concentrate from Tanbreez would not only de-risk Ucore’s operations but also send a strong signal to end users and policymakers that alternatives to Chinese dominance in the sector are viable.

The timing of this agreement is particularly significant given the surging demand for rare earths globally. Market research forecasts suggest that demand for rare earth magnets alone could more than double by 2035, driven primarily by the rapid adoption of electric vehicles and renewable energy systems (https://ibn.fm/V1FOw). Without new sources of heavy rare earth supply, the West risks a supply shortfall that could derail ambitious clean energy transition goals and compromise the production of critical defense technologies. Ucore’s LOI with Critical Metals represents a proactive response to these challenges, bringing certainty and visibility to a sector that has long been marked by volatility and geopolitical risk.

While Ucore’s LOI with Critical Metals is currently non-binding, it lays the groundwork for a definitive supply agreement that would give the company a durable competitive advantage in the global rare earth race. The company continues to advance engineering and financing for its Louisiana facility, with construction targeted to align with the anticipated start of feedstock deliveries in 2027. With support from both the private sector and the U.S. government, Ucore’s vision is rapidly taking shape as one of the most ambitious efforts to date to secure domestic rare earth independence.

From Greenland’s resource-rich Tanbreez deposit to Louisiana’s cutting-edge processing hub, Ucore is stitching together the pieces of a supply chain that could alter the trajectory of rare earth independence in North America. By securing a potential decade of feedstock through the agreement, the company is not only addressing the immediate needs of its Pentagon-backed facility but is also charting a course toward long-term resilience in one of the world’s most strategically important markets. In doing so, Ucore underscores its commitment to building a rare earth future that is not only technologically advanced but also geopolitically secure, ensuring that North America can compete and thrive in the global clean energy and defense landscapes.

For more information, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• ONAR Holding Corp. recently announced its revenue growth, financial performance, and updates on its capital strategy
• The announcement states strategic and corporate adjustments, including adding several new members to the board
• The company provided updates about Cortex, its proprietary marketing intelligence system, and a recent acquisition the company made to enhance the capabilities of Cortex

ONAR Holding Corp. (OTCQB: ONAR), a technology-first network of marketing companies, recently announced its Q2 results for 2025. The company announced that revenue grew 28% compared to Q2 last year, which reflects the growth and adoption the company has experienced lately.

However, despite this growth, the company reported a net loss overall. Much of the loss was driven by a few non-operating expenses like stock-based compensation, public company compliance costs, and others. 

These are important requirements for the company, and it stated that as it acquires more companies and expands its revenue base, these costs will eventually represent a smaller amount of total expenses.

ONAR repaid nearly $300,000 in principal and converted around $142,000 of debt into equity. The company also announced it has started the process of closing its Series E financing round, which showcases the growing investor interest in the platform.

The announcement mentioned strategic changes. Chief among them is the appointment of former MDC Partners Chairman and CEO Scott Kauffman as Chairman of the Board (ibn.fm/p951P).

It mentions adding Mark Gazit and Reda Raad as independent directors, as well as referencing past appointments of Jon Bond, former founder of Kirshbaum & Bond and CEO of White Ops, and Howard Palefsky, who has led multiple companies to billions of dollars in exits. These experts bring decades of technology and marketing experience to the organization.

ONAR highlights the progress made on the technology side. In particular, the company has advanced the roadmap for Cortex, which already serves as the foundation for performance marketing, media planning and data analysis across ONAR’s agency network. By integrating multiagent architecture into Cortex, ONAR intends to redefine how marketing services are delivered, emphasizing speed, efficiency and intelligent automation without sacrificing creative and strategic depth.

Not only did it partner with IQSTEL’s Reality Border division to co-develop an AI operating platform that will act as the foundation of Cortex but it also acquired customer intelligence platform Retina.ai. Both help boost the potential scope of Cortex and its capabilities.

The announcement ends with a statement that each of these achievements builds on the company vision to create an AI-powered marketing network that changes how brands can scale.

ONAR acquires best-in-class marketing agencies to service middle-market and growth stage companies by leveraging proprietary AI & technology.

For more information, visit the company’s website at www.ONAR.com.

NOTE TO INVESTORS: The latest news and updates relating to ONAR are available in the company’s newsroom at https://ibn.fm/ONAR

• SEGG Media recently announced the resounding success of its inaugural Racing Women Training Camp, powered by Sports.com
• The initiative was organized in partnership with Racing Women LLC, founded by Graeme Glew, who described the event as a breakthrough moment
• For the company, the camp aligned with a broader strategy to leverage sports and entertainment platforms to generate sustainable shareholder value

The world of motorsport has long been defined by speed, skill and spectacle, but for decades, it has also struggled with inclusivity. SEGG Media (NASDAQ: SEGG, LTRYW), a leader in sports, entertainment and gaming, is taking bold steps to help change that narrative. The company recently announced the resounding success of its inaugural Racing Women Training Camp, powered by Sports.com, marking a significant milestone in both the company’s growth strategy and the broader movement to expand opportunities for women in motorsport (ibn.fm/6VLvi).

The camp, held last month, brought together eight women from the United States, the United Kingdom, Hungary, Dubai and Qatar for four days of training and development across some of the most iconic racing venues in England. These aspiring drivers immersed themselves in a comprehensive program designed to hone both their physical performance and mental resilience, receiving mentorship from respected figures in the racing community. The initiative, which combined technical training, competitive racing and motivational workshops, highlighted SEGG Media’s vision for using sports as a platform for empowerment, innovation and long-term brand growth.

Throughout the program, participants received world-class instruction. At the Silverstone iZone Performance Center, the women received driver training using state-of-the-art simulation technology guided by Marcus Littlewood and Ian Aguilera. They also competed at Daytona Motorsport, where three participants — Lena Galyo, Ella Davies and Roshni Dudhiya — secured podium finishes, underscoring the potential that exists when talented women drivers are given proper opportunities and resources. The camp culminated at Donington Park, where Radical Motorsport provided high-speed factory passenger experiences that allowed participants to feel the power of competitive racing firsthand.

The initiative was organized in partnership with Racing Women LLC, founded by Graeme Glew, who described the event as a breakthrough moment. “These women came from all over the world, and they all went away with big smiles,” Glew noted, emphasizing the excitement and camaraderie fostered through the program. His comments underscored the event’s dual impact: Creating memorable experiences for participants while also signaling to the motorsport world that female drivers are ready to compete at elite levels.

For SEGG Media, the camp represented more than a one-off event. It is aligned with a broader strategy to leverage sports and entertainment platforms to generate sustainable shareholder value. As SEGG Media chair and CEO Matthew McGahan explained, programs like the Racing Women Training Camp do more than create opportunities for young athletes; they also build brand exposure, open doors for long-term sponsorships and reinforce SEGG Media’s commitment to inclusive, ethical engagement in global sports.

The timing of the initiative was also strategic. SEGG Media has been expanding its presence across the motorsport landscape, with executives attending the Daytona 500 as guests of NASCAR and sponsoring three drivers at the historic Milwaukee Mile. These efforts reflect the company’s ambition to deepen its footprint in competitive racing, with potential entry into the 2026 NASCAR season under active consideration. The Racing Women Training Camp adds another dimension to these efforts, combining commercial strategy with social impact by championing diversity in a historically male-dominated sport.

SEGG Media’s portfolio extends well beyond motorsport (ibn.fm/3Fsea). Through its flagship platform Sports.com, the company is building a hub for immersive fan engagement and digital storytelling. SEGG Media also operates Concerts.com, which expands its reach into the live entertainment sector, and maintains an interest in the gaming and lottery spaces through partnerships and Lottery.com brand initiatives. By bringing these properties under one umbrella, SEGG Media aims to redefine how audiences interact with sports and entertainment content in the digital age. 

What makes SEGG Media’s approach distinctive is its ability to combine commercial opportunity with cultural relevance. By launching programs such as the Racing Women Training Camp, the company is not only creating value for shareholders but also contributing to broader social conversations about diversity, representation and opportunity in sports. This dual impact helps SEGG Media position as a company that can thrive financially while also cultivating good will and recognition among fans, athletes and partners worldwide.

Looking ahead, SEGG Media has signaled its intent to continue expanding its involvement in sports and entertainment properties that offer both financial growth and cultural resonance. With the successful completion of its inaugural Racing Women Training Camp, the company has demonstrated its capacity to execute complex, meaningful initiatives while building momentum for its broader portfolio. 

For more information, visit the company’s website at SEGGMediaCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to SEGG are available in the company’s newsroom at https://ibn.fm/SEGG

• Nutriband sustains itself through multiple revenue-generating subsidiaries
• At the core of the company’s innovation is the AVERSA(TM) platform, a proprietary abuse-deterrent transdermal technology
• AVERSA(TM) fentanyl is projected to achieve peak annual sales of $200 million upon FDA approval, with upside potential exceeding $800 million

The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company’s lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive agents to prevent misuse, abuse and accidental exposure of drugs with high abuse potential, particularly opioids (ibn.fm/1qrav). With AVERSA(TM), Nutriband is aiming to transform traditional transdermal patches into safer tools for patients who require powerful pain relief, while simultaneously reducing the risks that have fueled a national epidemic.

Melnik opened his presentation by highlighting the company’s origins and growth trajectory since its founding in 2016. Nutriband, which completed its IPO in 2021, is structured differently from many biotechnology companies. Instead of relying solely on investor capital while burning through development costs, Nutriband sustains itself through multiple revenue-generating subsidiaries. These include 4P Therapeutics, a clinical consulting and regulatory program arm; Pocono Pharmaceuticals, which provides contract manufacturing services; and Active Intelligence, a sports recovery and kinesiology tape business. Together, these subsidiaries generate revenue that offsets the company’s development costs and reduces its reliance on dilutive fundraising.

At the core of Nutriband’s innovation is the AVERSA™ platform, a proprietary abuse-deterrent transdermal technology. Melnik explained that AVERSA(TM) can be applied to any existing transdermal patch, but the company’s lead candidate is an abuse-deterrent fentanyl patch. The technology is designed to interfere with the primary methods of opioid patch misuse, including chewing, snorting, brewing into tea or extracting the drug for alternative consumption. When an attempt is made to tamper with the AVERSA(TM) patch, the aversive agents are activated, rendering the opioid unusable and reducing the likelihood of abuse. Melnik emphasized that the deterrent components do not interfere with the drug’s therapeutic effect during normal prescribed use.

The need for this innovation is significant. According to the U.S. Centers for Disease Control and Prevention, more than 80,000 opioid overdose deaths were recorded in 2024, a crisis that has continued into subsequent years (ibn.fm/POBas). Fentanyl patches, though vital for many patients with severe chronic pain, remain especially vulnerable to diversion and misuse. Melnik cited data showing that 70% of fentanyl patch abusers ingest the drug orally, making oral deterrence mechanisms a crucial feature of the AVERSA(TM) technology.

He also noted the tragic instances of accidental exposure, including 32 recorded cases resulting in 12 deaths, often among young children. By addressing both intentional misuse and accidental harm, Nutriband’s AVERSA(TM) aims to significantly improve the safety profile of opioid patches.

The commercial potential is substantial. Based on third-party assessments, AVERSA(TM) fentanyl is projected to achieve peak annual sales of $200 million upon U.S. Food and Drug Administration (“FDA”) approval, with upside potential exceeding $800 million if the FDA were to mandate abuse-deterrent formulations for all fentanyl patches, like its requirement for oxycodone in prior years. In June 2025, Nutriband announced that it had completed commercial-scale manufacturing of AVERSA(TM) in partnership with Kindeva, a leading global contract development and manufacturing organization specializing in transdermal systems (ibn.fm/00DvY). The company is preparing to manufacture clinical supplies and file an Investigational New Drug (“IND”) application with the FDA to initiate human abuse liability studies, the pivotal trial required before formal FDA submission.

Melnik noted that the company expects the pivotal phase 1 study, which compares AVERSA(TM) Fentanyl against conventional patches, to demonstrate the technology’s ability to resist tampering and misuse. Following that study, Nutriband plans to submit its application to the FDA within the next 12 months, targeting potential approval in late 2026 or early 2027. Meanwhile, Nutriband has secured patents protecting AVERSA(TM) in 47 countries, including recent approvals in China, Hong Kong and Macau, strengthening its global commercialization prospects.

Beyond fentanyl, Nutriband is also developing AVERSA formulations for buprenorphine and methylphenidate patches, extending the platform into additional therapeutic areas where transdermal delivery intersects with drugs prone to abuse. Melnik emphasized that AVERSA(TM) is not limited to one product but represents a scalable platform technology that can be applied across multiple classes of drugs.

Finally, Melnik contrasted Nutriband’s approach with the traditional biotech model. He highlighted that Nutriband has not returned to public markets for dilutive capital raises since its IPO in 2021, thanks in part to revenue streams from its subsidiaries and disciplined financial management. This structure, he noted, enables the company to pursue innovation in abuse-deterrent technology while protecting shareholder value.

Nutriband’s AVERSA(TM) represents a novel attempt to combine patient access to effective pain management with enhanced safety for the public at large. If successful, the technology could reshape not only the transdermal market but also the broader landscape of opioid safety, aligning with Nutriband’s stated mission of developing science-based, values-driven innovations that improve patient lives while addressing urgent public health challenges.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB